{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:45:38Z","timestamp":1789933538250,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.clinthera.2014.02.008","type":"journal-article","created":{"date-parts":[[2014,3,11]],"date-time":"2014-03-11T08:36:22Z","timestamp":1394526982000},"page":"534-543","source":"Crossref","is-referenced-by-count":15,"title":["Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in Thailand"],"prefix":"10.1016","volume":"36","author":[{"given":"Wantanee","family":"Kulpeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumalai","family":"Sompitak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saengsuree","family":"Jootar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchana","family":"Chansung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yot","family":"Teerawattananon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9 Suppl 2","key":"10.1016\/j.clinthera.2014.02.008_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.6004\/jnccn.2011.0125","article-title":"NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia","author":"O\u2019Brien","year":"2011","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clinthera.2014.02.008_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6330","article-title":"The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: a systematic review","volume":"6","author":"Garside","year":"2002","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.clinthera.2014.02.008_bib3","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","article-title":"Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"29","author":"Steinberg","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.02.008_bib4","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.leukres.2010.03.033","article-title":"Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era","volume":"34","author":"Kim","year":"2010","journal-title":"Leuk Res"},{"key":"10.1016\/j.clinthera.2014.02.008_bib5","first-page":"25","article-title":"Multivariate analysis of prognostic factors in Philadelphia chromosome positive chronic myeloid leukemia: an update of the first series in Thailand","volume":"14","author":"Jootar","year":"1996","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.clinthera.2014.02.008_bib6","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.02.008_bib7","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2014.02.008_bib8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/0284186X.2010.495132","article-title":"Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application","volume":"49","author":"Ghatnekar","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clinthera.2014.02.008_bib9","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.clinthera.2008.11.014","article-title":"Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia","volume":"30","author":"Deremer","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.02.008_bib10","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2014.02.008_bib11","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.02.008_bib12","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.critrevonc.2012.03.005","article-title":"The expanding options for front-line treatment in patients with newly diagnosed CML","volume":"84","author":"Pinilla-Ibarz","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clinthera.2014.02.008_bib13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.blre.2011.02.001","article-title":"Interpretation of cytogenetic and molecular results in patients treated for CML","volume":"25","author":"Vigil","year":"2011","journal-title":"Blood Rev"},{"key":"10.1016\/j.clinthera.2014.02.008_bib14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.02.008_bib15","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2014.02.008_bib16","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2012.181","article-title":"Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clinthera.2014.02.008_bib17","first-page":"1103","article-title":"Correlation of Different Responses to Imatinib on Survival of Patients (pts) with Chronic Myelogenous Leukemia (CML) in Accelerated (AP) and Blast Phase (BP)","volume":"106","author":"Aoki","year":"2005","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clinthera.2014.02.008_bib18","article-title":"Current practice, financing and policy on terminally ill patients in Thailand. School of Medicine, Health Policy and Practice, Faculty of Health","author":"Akaleephan","year":"2010","journal-title":"University of East Anglia"},{"key":"10.1016\/j.clinthera.2014.02.008_bib19","unstructured":"The Comptroller General\u2019s Department. Database of standard costs of health care survices under the Ministry of Public Health. 2012; http:\/\/welcgd.cgd.go.th\/welcgd1\/searchbase\/. Accessed June 18, 2012."},{"key":"10.1016\/j.clinthera.2014.02.008_bib20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2007-07-103523","article-title":"Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment","volume":"111","author":"Hochhaus","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.02.008_bib21","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2014.02.008_bib22","unstructured":"The World Health Organization. Global Health Observatory Data Repository 2012; http:\/\/apps.who.int\/ghodata\/?vid=720#apps.who.int\/ghodata\/. Accessed June 15, 2012."},{"key":"10.1016\/j.clinthera.2014.02.008_bib23","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jval.2011.06.005","article-title":"Estimating population-based values for EQ-5D health states in Thailand","volume":"14","author":"Tongsiri","year":"2011","journal-title":"Value Health"},{"issue":"91 Suppl 2","key":"10.1016\/j.clinthera.2014.02.008_bib24","first-page":"S1","article-title":"The need for guidelines and the use of economic evidence in decision-making in Thailand: lessons learnt from the development of the national list of essential drugs","author":"Wibulpolprasert","year":"2008","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.clinthera.2014.02.008_bib25","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.02.008_bib26","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1182\/blood-2001-12-0181","article-title":"A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias","volume":"100","author":"Ottmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2014.02.008_bib27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1182\/asheducation-2010.1.122","article-title":"Chronic myeloid leukemia 2010: where are we now and where can we go?","volume":"2010","author":"Radich","year":"2010","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clinthera.2014.02.008_bib28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","article-title":"Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia","volume":"14","author":"Hoyle","year":"2011","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2014.02.008_bib29","unstructured":"Thai Chronic Myeloid Leukemia Working Group and The Thai Society of Hematology. Treatment guideline for chronic myeloid leukemia in Thailand. 2011."},{"key":"10.1016\/j.clinthera.2014.02.008_bib30","first-page":"17","article-title":"A feasibility study of allogeneic hematopoietic stem cell transplantation for severe thalasemic patients covered by the Universal Coverage Scheme. 2012","author":"Kotirum","year":"2014","journal-title":"February"},{"key":"10.1016\/j.clinthera.2014.02.008_bib31","unstructured":"National Institute for Health and Clinical Excellence. Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance. 2012. http:\/\/guidance.nice.org.uk\/TA241. Accessed February 17, 2014."},{"key":"10.1016\/j.clinthera.2014.02.008_bib32","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814000770?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814000770?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T05:53:49Z","timestamp":1565243629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814000770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0149291814000770"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.02.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}